

SPRING GROUP MEETING

# Seattle

# Immunotherapeutics Committee

APRIL 3-6, 2024 | SEATTLE, WASHINGTON

# Immunotherapeutics Committee

## Leadership

Co-Chairs: ..... Siwen Hu-Lieskovan, MD, PhD  
 ..... Katerina Politi, PhD  
 Executive Officer: ..... Anne Chi-An Chiang, MD, PhD  
 Statisticians: ..... Michael LeBlanc, PhD  
 ..... Katie Minichiello, MS  
 ..... James Moon, MS  
 Data Coordinator: ..... Matt Gospe  
 Pharmaceutical Science: ..... Jordan P. McPherson, PharmD  
 ..... Kimberly McConnell, PharmD  
 Protocol Project Manager: ..... Chris Kippola  
 Clinical Trial Program Manager: ..... Laura Gildner, MS

## Time/Location

Thursday, April 4, 2024 1:00 p.m. - 3:00 p.m.  
 Room: Chiliwack / 402 (Level 4)

## Agenda

1:00 – 1:20 pm Developing Predictors of Immunotherapy using Big Data  
 Eytan Ruppin, MD, PhD  
 Senior Investigator, National Cancer Institute  
 Chief, Cancer Data Science Laboratory

1:20 – 1:30 pm Q & A

1:30 – 1:40 pm S2101 iMATCH Pilot – Trial Update  
 Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan

1:40 – 1:45 pm Q & A

1:45 – 1:55 pm S2013 I-CHECKIT – Trial Update  
 Krishna Soujanya Gunturu, MD  
 Associate Chief, Clinical Trials & Correlative Science  
 Research, Hartford HealthCare Cancer Institute

1:55 – 2:00 pm Q & A

2:00 – 2:10 pm A151804: Establishment of a National Biorepository to  
 Advance Studies of Immune-Related Adverse Events –  
 Trial Update  
 David E. Kozono, MD, PhD  
 A151804 Study Chair  
 Assistant Professor of Radiation Oncology, Harvard  
 Medical School  
 Director, Thoracic Radiation Oncology

2:10 – 2:15 pm Q & A

2:15 – 2:25 pm SITC's Resistance Data Collection Effort, led by SITC's  
 Immunotherapy Resistance Committee  
 Harriet Kluger, MD  
 Harvey and Kate Cushing Professor of Oncology and of  
 Dermatology  
 Director, Yale SPORE in Skin Cancer, Yale Cancer Center

Ryan Sullivan, MD  
 Associate Professor of Medicine, Harvard Medical School  
 Physician Investigator (CI), Cancer Center, Mass General  
 Research Institute

Hussein Tawbi, MD, PhD  
 Deputy Chair, Department of Melanoma Medical  
 Oncology  
 Co-Director, MD Anderson Brain Metastasis Clinic

2:25 – 2:30 pm Q & A

2:30 – 2:50 pm Genomic and Immunophenotypic Landscape of  
 Acquired Resistance to PD-(L)1 Blockade in Non-Small-  
 Cell Lung Cancer  
 Mark Awad, MD, PhD  
 Assistant Professor of Medicine, Harvard Medical School  
 Director, Lowe Center for Thoracic Oncology, Dana-Farber  
 Cancer Institute

2:50 – 2:55 pm Q & A

2:55 – 3:00 pm Closing Remarks

## Active Study

**S2101**, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi.  
 Activation: 10/14/22.

## Publications

### Published/Accepted Manuscripts

None this cycle

### Submitted Manuscripts

None this cycle

## Immunotherapeutics Committee

**Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study**

|  |           |
|--|-----------|
|  | S2101     |
| <i>Essentia Health NCI Community Oncology Research Program</i> | 1         |
| <i>Heartland Cancer Research NCORP</i>                         | 1         |
| <i>New Mexico Minority Underserved NCORP</i>                   | 1         |
| <i>Northwestern University LAPS</i>                            | 1         |
| <i>Pacific Cancer Research Consortium NCORP</i>                | 1         |
| <i>University of Michigan Comprehensive Cancer Center LAPS</i> | 9         |
| <i>University of Utah - Huntsman Cancer Institute LAPS</i>     | 5         |
| ALLIANCE   | 4         |
| ECOG-ACRIN   | 3         |
| NRG  | 1         |
| <b>Total</b>   | <b>27</b> |

